Abstract
Despite advances in technology, the formidable challenge of treating cancer, especially if advanced, still remains with no significant improvement in survival rates, even with the most common forms of cancer. Oncolytic viral therapies have shown great promise for the treatment of various cancers, with the possible advantages of stronger treatment efficacy compared to conventional therapy due to higher tumor selectivity, and less toxicity. They are able to preferentially and selectively propagate in cancer cells, consequently destroying tumor tissue mainly via cell lysis, while leaving non-cancerous tissues unharmed. Several wild-type and genetically engineered vaccinia virus (VACV) strains have been tested in both preclinical and clinical trials with promising results. Greater understanding and advancements in molecular biology have enabled the generation of genetically engineered oncolytic viruses for safer and more efficacious treatment, including arming VACVs with cytokines and immunostimulatory molecules, anti-angiogenic agents, and enzyme prodrug therapy, in addition to combining VACVs with conventional external and systemic radiotherapy, chemotherapy, immunotherapy, and other virus strains. Furthermore, novel oncolytic vaccinia virus strains have been generated that express reporter genes for the tracking and imaging of viral therapy and monitoring of therapeutic response. Further study is needed to unlock VACVs’ full potential as part of the future of cancer therapy.
Highlights
Replication-competent oncolytic viral therapies have shown great promise preclinically and in clinical trials for the treatment of various cancers
Partial remissions have been reported in patients with metastatic renal or pulmonary carcinomas [19, 20]. These findings lead to several clinical trials including treating melanoma with a potent vaccinia virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) [21, 22]
An oncolytic vaccinia virus carrying human norepinephrine transporter (hNET), GLV-1h99 derived from GLV-1h68, mediated the expression of the hNET protein on the cell surface of infected tumor cells, resulting in specific uptake of the radiotracer [131I]-MIBG [35]
Summary
Oncolytic viral therapies have shown great promise for the treatment of various cancers, with the possible advantages of stronger treatment efficacy compared to conventional therapy due to higher tumor selectivity, and less toxicity. They are able to preferentially and selectively propagate in cancer cells, destroying tumor tissue mainly via cell lysis, while leaving non-cancerous tissues unharmed. Greater understanding and advancements in molecular biology have enabled the generation of genetically engineered oncolytic viruses for safer and more efficacious treatment, including arming VACVs with cytokines and immunostimulatory molecules, anti-angiogenic agents, and enzyme prodrug therapy, in addition to combining VACVs with conventional external and systemic radiotherapy, chemotherapy, immunotherapy, and other virus strains.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have